Patupilone (Epothilone B) for recurrent glioblastoma: Clinical outcome and translational analysis of a single-institution phase I/II trial by Oehler, C et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2012
Patupilone (Epothilone B) for recurrent glioblastoma: Clinical outcome and
translational analysis of a single-institution phase I/II trial
Oehler, C; Frei, K; Rushin, E J; McSheehy, P M J; Weber, D; Allegrini, P R; Weniger, D; Lütolf, U M;
Knuth, A; Yonekawa, Y; Barath, K; Broggini-Tenzer, A; Pruschy, M; Hofer, S
Abstract: Background: Patients with glioblastoma (GBM) inevitably develop recurrent or progressive
disease after initial multimodal treatment and have a median survival of 6-9 months from time of pro-
gression. To date, there is no accepted standard treatment for GBM relapse or progression. Patupilone
(EPO906) is a novel natural microtubule-stabilizing cytotoxic agent that crosses the blood-brain barrier
and has been found to have preclinical activity in glioma models. Methods: This is a single-institution,
early-phase I/II trial of GBM patients with tumor progression who qualified for second surgery with
the goal of evaluating efficacy and safety of the single-agent patupilone (10 mg/m(2), every 3 weeks).
Patients received patupilone 1 week prior to second surgery and every 3 weeks thereafter until tumor
progression or toxicity. Primary end points were progression-free survival (PFS) and overall survival (OS)
at 6 months as well as patupilone concentration in tumor tissue. Secondary end points were toxicity,
patupilone concentration in plasma and translational analyses for predictive biomarkers. Results: Nine
patients with a mean age of 54.6 ± 8.6 years were recruited between June 2008 and April 2010. Median
survival and 1-year OS after second surgery were 11 months (95% CI, 5-17 months) and 45% (95% CI,
14-76), respectively. Median PFS was 1.5 months (95% CI, 1.3-1.7 months) and PFS6 was 22% (95%
CI, 0-46), with 2 patients remaining recurrence-free at 9.75 and 22 months. At the time of surgery, the
concentration of patupilone in tumor tissue was 30 times higher than in the plasma. Tumor response was
not predictable by the tested biomarkers. Treatment was generally well tolerated with no hematological,
but cumulative, though reversible sensory neuropathy grade ￿3 was seen in 2 patients (22%) at 8 months
and grade 4 diarrhea in the 2nd patient (11%). Non-patupilone-related peri-operative complications oc-
curred in 2 patients resulting in discontinuation of patupilone therapy. There were no neurocognitive
changes 3 months after surgery compared to baseline. Conclusions: In recurrent GBM, patupilone can be
given safely pre- and postoperatively. The drug accumulates in the tumor tissue. The treatment results
in long-term PFS in some patients. Patupilone represents a valuable novel compound which deserves
further evaluation in combination with radiation therapy in patients with GBM.
DOI: 10.1159/000339152
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-63572
Published Version
Originally published at:
Oehler, C; Frei, K; Rushin, E J; McSheehy, P M J; Weber, D; Allegrini, P R; Weniger, D; Lütolf,
U M; Knuth, A; Yonekawa, Y; Barath, K; Broggini-Tenzer, A; Pruschy, M; Hofer, S (2012). Patupi-
lone (Epothilone B) for recurrent glioblastoma: Clinical outcome and translational analysis of a single-
institution phase I/II trial. Oncology, 83(1):1-9. DOI: 10.1159/000339152
2
Fax +41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com
 Clinical Study 
 Oncology 2012;83:1–9 
 DOI: 10.1159/000339152 
 Patupilone (Epothilone B) for Recurrent 
Glioblastoma: Clinical Outcome and Translational 
Analysis of a Single-Institution Phase I/II Trial 
 Christoph Oehler a    Karl Frei b    Elisabeth J. Rushing c    Paul M.J. McSheehy g    
Dirk Weber g    Peter R. Allegrini g    Dorothea Weniger d    Urs M. Lütolf a    
Alexander Knuth e    Yasuhiro Yonekawa b    Krisztina Barath f    
Angela Broggini-Tenzer a    Martin Pruschy a    Silvia Hofer e 
 Departments of  a  Radiation Oncology,  b  Neurosurgery,  c  Neuropathology,  d  Neurology,  e  Oncology and 
 f  Neuroradiology, University Hospital Zürich,  Zürich , and  g  Department of Clinical Development Oncology,
Novartis Pharma AG,  Basel , Switzerland 
analyses for predictive biomarkers.  Results: Nine patients 
with a mean age of 54.6  8 8.6 years were recruited between 
June 2008 and April 2010. Median survival and 1-year OS af-
ter second surgery were 11 months (95% CI, 5–17 months) 
and 45% (95% CI, 14–76), respectively. Median PFS was 1.5 
months (95% CI, 1.3–1.7 months) and PFS6 was 22% (95% CI, 
0–46), with 2 patients remaining recurrence-free at 9.75 and 
22 months. At the time of surgery, the concentration of patu-
pilone in tumor tissue was 30 times higher than in the plas-
ma. Tumor response was not predictable by the tested bio-
markers. Treatment was generally well tolerated with no 
 hematological, but cumulative, though reversible sensory 
neuropathy grade  ^  3 was seen in 2 patients (22%) at 8 
months and grade 4 diarrhea in the 2nd patient (11%). Non-
patupilone-related peri-operative complications occurred 
in 2 patients resulting in discontinuation of patupi lone ther-
apy. There were no neurocognitive changes 3 months after 
surgery compared to baseline.  Conclusions: In recurrent 
GBM, patupilone can be given safely pre- and postopera-
tively. The drug accumulates in the tumor tissue. The treat-
ment results in long-term PFS in some patients. Patupilone 
represents a valuable novel compound which deserves fur-
ther evaluation in combination with radiation therapy in pa-
tients with GBM.  Copyright © 2012 S. Karger AG, Basel 
 Key Words 
 Recurrent glioblastoma   Patupilone   Epothilone B   
Translational research 
 Abstract 
 Background: Patients with glioblastoma (GBM) inevitably 
develop recurrent or progressive disease after initial multi-
modal treatment and have a median survival of 6–9 months 
from time of progression. To date, there is no accepted stan-
dard treatment for GBM relapse or progression. Patupilone 
(EPO906) is a novel natural microtubule-stabilizing cytotoxic 
agent that crosses the blood-brain barrier and has been 
found to have preclinical activity in glioma models.  Meth-
ods: This is a single-institution, early-phase I/II trial of GBM 
patients with tumor progression who qualified for second 
surgery with the goal of evaluating efficacy and safety of the 
single-agent patupilone (10 mg/m 2 , every 3 weeks). Patients 
received patupilone 1 week prior to second surgery and ev-
ery 3 weeks thereafter until tumor progression or toxicity. 
Primary end points were progression-free survival (PFS) and 
overall survival (OS) at 6 months as well as patupilone con-
centration in tumor tissue. Secondary end points were toxic-
ity, patupilone concentration in plasma and translational 
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 Introduction 
 Patients with glioblastoma (GBM) inevitably develop 
recurrent or progressive disease after initial treatment, 
which comprises gross tumor resection followed by ra-
diation therapy (RT), and concomitant and adjuvant te-
mozolomide (TMZ)  [1] . At recurrence, median overall 
survival (OS) is approximately 6–9 months  [2–5] . To 
date, there is no standard treatment for recurrent dis-
ease. 
 A variety of treatment modalities have been investi-
gated for recurrent GBM. Most commonly, systemic ther-
apy is used, while some institutions apply a second round 
of local treatment, including second surgery, second RT 
or experimental local treatment options  [6] . Second sur-
gery alone results in very limited survival prolongation 
requiring additional postoperative systemic therapy  [7, 
8] . Treatments offered are TMZ, nitrosoureas, PCV (pro-
carbazine, CCNU and vincristine), cyclophosphamide, 
platinum-based regimens or, more recently, bevacizu-
mab, an antibody against VEGF  [9] . Following single-
agent therapy, progression-free survival (PFS) at 6 months 
results range from 20 to 30% without bevacizumab and 
up to 45% with bevacizumab  [4] .
 Patupilone is a novel, well-tolerated microtubule-sta-
bilizing agent belonging to the group of epothilones, 
which are not cross-resistant with taxanes. They are cur-
rently being tested in phase I–III trials  [10, 11] . Patupilo-
ne has a higher affinity for the   III-tubulin subunit of 
microtubules than the taxanes and has been shown to be 
active in   III-tubulin-overexpressing cell lines  [12] . It 
has a long half-life (89 h) in tumor tissue and is known 
to cross the blood-brain barrier in mice, rats and
dogs  [13] . Preclinical studies have demonstrated activity 
against glioma/medulloblastoma cell lines as well as 
multidrug-resistant cell lines due to the independency of 
patupilone of the efflux pump P-glycoprotein, which is 
abundant in glioma cells and the blood-brain barrier 
 [13–15] . Patupilone is cytotoxic to ex vivo GBM cell cul-
tures [K. Frei, pers. commun.] and murine intracranial 
tumors  [16, 17] .
 Furthermore, patupilone is known to have anti-angio-
genic effects via paracrine activity at the level of VEGF 
secretion and other factors  [18, 19] . This anti-angiogenic 
activity can be detected by magnetic resonance imaging 
(MRI)  [20–22] . Of note, the effect of patupilone is inde-
pendent of tumor hypoxia  [18] . Combination therapy of 
patupilone with other agents such as imatinib or ioniz-
ing radiation results in synergistically enhanced effects 
against subcutaneous experimental tumor xenografts, 
e.g. rat C6 gliomas and medulloblastomas  [15, 23] . In a 
phase I trial in patients with central nervous system ma-
lignancies, combined treatment with ionizing radiation 
was well tolerated and safe, which supports further study 
of this regimen in the upfront setting in GBM  [24] .
 Patients and Methods 
 Study Design and Patient Selection 
 The study was designed as a single-institution (University 
Hospital Zürich), open-label, early-phase I–II study of patupilone 
to explore single-agent activity, toxicity, pharmacokinetics and 
correlative translational biomarkers in GBM patients at first re-
currence/progression after standard surgery and chemoradiation 
according to the EORTC 22981/26981 protocol  [1] . Eligible pa-
tients were adults ( 1 18 years) with a histologically proven GBM 
according to World Health Organization (WHO) criteria (2007), 
radiologically (MRI) measurable tumor  6 2 cm and eligibility for 
second surgery. Patients requiring enzyme-inducing anti-epilep-
tic therapy were switched to a non-enzyme-inducing compound. 
Other eligibility criteria included a WHO performance status of 
0–1, normal hematological function (leukocytes  6 3  ! 10 9 cells/l, 
platelets  6 100  ! 10 9 cells/l, hemoglobin  6 9 g/dl) and adequate 
hepatic [bilirubin  ! 1.5  ! upper limit of the normal (ULN) range, 
alkaline phosphatase and transaminases (ASAT-ALAT)  ! 2.5  ! 
ULN] and renal function (serum creatinine  ! 1.5  ! ULN;  fig. 1 ).
 All patients gave written informed consent and the study was 
approved by the local ethics committee. The study was conducted 
in accordance with the Declaration of Helsinki and Good Clinical 
Practice Guidelines. The trial was registered at clinicaltrials.gov 
(NCT00715013). The protocol was amended for more rigorous 
dose adjustments following grade 4 diarrhea in patient 2.
 End Points 
 Primary end points were patupilone concentration in glioma 
tissue with respect to its level in the blood, and PFS and OS at 4 
and 6 months. Secondary end points included pharmacokinetics 
of patupilone in plasma, toxicity/safety, neurocognitive changes, 
predictive biomarkers and MRI-based evaluation of blood vol-
ume parameters before and after the first patupilone dose. Ad-
verse events were recorded according to the National Cancer In-
stitute-Common Toxicity Criteria (version 3.0).
 Statistical Analysis 
 Initially, the study was intended as a two-sided, two-stage tri-
al: 16 patients in the first step and another 16 patients in the sec-
ond step, resulting in a total of 32 patients. The number of patients 
was calculated for P1 = 25% as the lowest response probability 
(which if true implied that therapeutic activity warranted further 
investigation) and P0 = 5% as the largest response probability 
(which if true implied that the therapeutic activity does not war-
rant further investigation).   and   errors chosen were 5 and 10%, 
respectively. The study was terminated prematurely and only de-
scriptive statistics were used due to the small number of patients. 
PFS and OS were calculated from the time of second surgery to 
disease progression or death (last update November 2011) accord-
ing to the Kaplan-Meier method using SPSS (IBM SPSS statistics 
19).
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 Treatment 
 Patupilone (EPO906) was administered in a ready-made solu-
tion of PEG-300 (10 mg/4 ml) during a 20-min infusion at a total 
dose of 10 mg/m 2 i.v. every 3 weeks. No specific premedication 
(e.g. antihistamines or anti-emetics) was recommended. Patients 
received patupilone at least 5 days prior to the second surgery. 
Patupilone was provided by Novartis, Basel, Switzerland. Baseline 
tumor imaging with MRI was carried out within 14 days before 
treatment start and every 2 months thereafter. Treatment was 
continued every 3 weeks until tumor progression, toxicity or pa-
tient refusal. In the event of any toxic manifestation (e.g. diarrhea 
or neuropathy), patupilone was reduced according to the proto-
col. The protocol was amended after the 2nd patient developed 
grade 4 diarrhea by prolonging the interval between surgery and 
the next patupilone dose from 3 to 4 weeks, a more rigorous med-
ical history of stool habits was obtained and loperamide prophy-
laxis was prescribed for loose stools.
 Salvage treatment after patupilone consisted of bevacizumab, 
CCNU, a second RT round or surgery.
 Evaluation 
 Clinical evaluation before each patupilone cycle included 
physical and neurological examination. Neuropsychological as-
sessment was carried out before and 3 months after surgery dur-
ing ongoing patupilone treatment. The 3-month time point was 
scheduled early to minimize overlapping neurocognitive dys-
function due to tumor progression. This assessment comprised 
the examination of expressive and receptive language functions 
with an abridged version of the Aachen Aphasia Test  [25] , an eval-
uation of verbal and visual memory functions with the Rey Audi-
tory-Verbal Learning Test and the Rey Visual Design Learning 
Test, and an appraisal of executive functioning with a set of tests 
that tap sustained and selective attention and conceptual flexibil-
ity. Visual-spatial abilities were evaluated with the Rey-Osterrieth 
Complex Figure Test, a visual search test (Bells Test) and a simple 
line bisection task.
 Complete blood count and blood chemistry were assessed 
before each chemotherapy cycle. For pharmacokinetic analysis, 
plasma concentrations of patupilone were determined on cycle 1 
and 2 prior to infusion, at the end of infusion, and at 1, 2, 120, 168 
and 504 h. Patupilone concentration in frozen tumor tissue, 
which was obtained during the second surgery, was analyzed us-
ing a high-performance liquid chromatography tandem mass 
spectrometry, as described by Blum et al.  [26] .
 Relative tumor blood volume (rTBV) was measured using a 
dynamic contrast-enhanced MRI (1.5-tesla GE scanner) prior to 
First patupilone i.v. 
Inclusion criteria:
• Recurrent or progressive GBM
• Second surgery planned
• Radiologically confirmed measurable lesion ≥2cm 
• After intial standard treatment for GBM 
• Patients must have recovered from the toxic effects
of prior therapy and interval must be at least 3 weeks 
• ≥18 years, KPS 70–100%, informed consent
• No enzyme-inducing drugs
= Neurocognitive evaluation
= DCE-MRI 
= Pharmacokinetics
= Tumor sample
= Translational research as described 
= MRI pre-  and postoperatively, thereafter every 2 months
2 3 4 months 
Surgery
Patupilone every 3 weeks
until tumor progression
 Fig. 1. Study design. DCE = Dynamic contrast enhancement; KPS = Karnofsky performance status. 
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and at least 120 h after the first patupilone dose. Dynamic mul-
tislice, T 2 * -weighted echoplanar imaging was performed using 
the following acquisition parameters: TE: 55 ms, temporal reso-
lution TR: 1.5–7.5 s, number of repetitions: 40 or 50, field of view: 
241  ! 241 mm 2 and slice thickness: 3–5 mm. The number of 
slices was chosen so as to capture the entire brain, i.e. 28–52 
slices. Images were obtained before contrast enhancement and 
after intravenous injection of 20 ml Gd chelate (Dotarem, 0.5 
mmol/ml) as a single bolus at an infusion rate of 20 ml/5 s with 
an injector (Medrad). rTBV was assessed by analyzing the first 
passage of the contrast agent  [27] . The signal decay induced by 
the contrast bolus was converted into relative contrast agent con-
centrations in a pixel-by-pixel manner. The resulting time cours-
es were then modeled by a   -variate fit to eliminate the contribu-
tion of tracer recirculation. The change in rTBV was expressed 
as fractional change of the integral of the   -variate curve as a 
result of patupilone treatment (rTBV after treatment/rTBV at 
baseline).
 In each case, tumor tissue collected during first and second 
surgery was evaluated. Immunohistochemistry was performed 
on 3-  m sections of formalin-fixed, paraffin-embedded tissue. 
Briefly, tissue sections were mounted on glass slides (SuperFrost 
Plus; Menzel, Braunschweig, Germany) and deparaffinized. For 
staining with the proliferation marker Ki-67, CC1 (antigen re-
trieval solution; Ventana)-pretreated sections were incubated 
with monoclonal rabbit Ki-67 antibody (clone SP6; Epitomics 
Inc., Burlingame, Calif., USA). Detection of primary antibody 
was performed with a goat anti-rabbit IgG HRP antibody (Jack-
son ImmunoResearch, West Grove, Pa., USA) and peroxidase de-
tected by 3,3-diaminobenzidine tetrahydrochloride (DAB; Dako, 
Carpinteria, Calif., USA). DNA fragmentation (apoptosis) was vi-
sualized by the deoxynucleotidyl transferase-mediated dUTP-bi-
otin nick-end labelling (TUNEL) reaction according to the man-
ufacturer’s instructions [ApopTag  peroxidase in situ oligo liga-
tion (ISOL) kit; Chemicon, Millipore AG, Zug, Switzerland]. The 
percentage of TUNEL- and Ki-67-positive cells was determined 
by counting 10 randomly chosen high-power fields.   III-Tubulin 
staining was performed with a polyclonal rabbit IgG (Abcam, 
Cambridge, UK) and visualized using an anti-rabbit IgG second-
ary antibody (Vectostain kit; Vector Laboratories, Burlingame, 
Calif., USA) and the peroxidase as detected by DAB (Dako, Glos-
trup, Denmark).
 A semiquantitative analysis was performed based on the fol-
lowing criteria: + =  ! 10% positive cells; ++ = 10–50% positive 
cells, and +++ =  1 50% positive cells. Negative controls were per-
formed using isotype antibodies followed by the appropriate sec-
ondary IgG HRP antibody. 
 For IDH1 R132H staining, antiYIDH1-R132H antibody clone 
DIA-H09 was obtained from Dianova (Hamburg, Germany) and 
the antibody concentration of 1: 200 was used. Briefly, formalin-
fixed, paraffin-embedded sections were placed in a Bond Max Au-
tomated Immunohistochemistry Vision BioSystem (Leica Micro-
systems, Wetzlar, Germany) according to the standard protocol. 
Briefly, sections were heated at 95   °   C using EDTA buffer (pH 8.8) 
for 20 min. After washing, peroxidase blocking was carried out for 
10 min using the Bond Polymer Refine Detection Kit DC9800 (Lei-
ca Microsystems). Tissues were again washed and then incubated 
with the primary antibody for 30 min. Subsequently, tissues were 
incubated with polymer for 10 min and developed with DAB (Dako) 
for 10 min. We defined cases with at least 10% cells as positive.
 For class I   -tubulin sequencing, frozen tumor material was 
homogenized in TRI Reagent  solution (Ambion, Austin, Tex., 
USA) and RNA was extracted according to the manufacturer’s 
protocol. cDNA preparation, PCR and sequencing were per-
formed by Microsynth (Balgach, Switzerland) using primers spe-
cific for human class I   -tubulin (GenBank accession No. J00314): 
forward primer TCGTGCACATCCAGGCTGGTC and reverse 
primer AGGCCTCCTCTTCGGCCTCC.
 Results 
 Patient and Tumor Characteristics 
 A total of 9 patients with histologically proven, recur-
rent GBM were recruited at the University Hospital 
Zürich from June 2008 to April 2010. Patient character-
istics at study entry are summarized in  table 1 . All pa-
tients were male, with a mean and median age of 54.6  8 
8.6 and 54 years, respectively, and WHO performance 
status was 0 or 1. All patients had received standard up-
front treatment for their GBM prior to study enrolment, 
including gross total resection, concurrent RT and che-
motherapy (TMZ) followed by TMZ for 1–6 cycles. Two 
of 9 patients had received TMZ on a 1-week-on, 1-week-
off regimen for recurrent disease and 6 of 9 patients (66%) 
were on steroids before being enrolled in the study. All 
GBM cases were negative for the  IDH -1 (isocitrate dehy-
drogenase-1) mutation and those tested for  MGMT gene 
promoter methylation (patients 4–9) were unmethylated, 
indicating a cohort of patients with a poor prognosis.
 Patupilone Distribution 
 A total of 54 cycles of patupilone (range 1–30/patient) 
were administered. Patupilone concentrations in plasma 
and tumor tissue were determined in 2 patients at the 
time of surgery, revealing a 30-fold patupilone accumula-
tion in the tumor tissue. In the 1st patient, patupilone 
concentrations were 1.58 ng/ml in the plasma and 43.4 
ng/g in the tumor tissue, and in the 2nd patient they were 
3.29 ng/ml and 208 ng/g, respectively. Pharmacokinetic 
findings were comparable to previous results (data not 
shown)  [11] . The maximum plasma patupilone concen-
tration was measured at the end of the 20-min infusion 
(1.6–3.3 ng/ml) followed by a steady decline.
 Response and Survival 
 Median survival after second surgery was 11 months 
(95% CI, 5–17 months) and 1-year OS was 45% (95% CI, 
14–76; online suppl. fig. 1a; for all online suppl. materi-
al, see www.karger.com/doi/10.1159/000339152). Median 
PFS was 1.5 months (95% CI, 1.3–1.7 months). PFS at 4 
 Patupilone for Recurrent Glioblastoma  Oncology 2012;83:1–9 5
and 6 months was 22% (PPF6 95% CI, 0–46), and 2 of 9 
patients were free of disease for 9.75 and 22 months on 
study treatment (online suppl. fig. 1b). Of note, 3 patients 
were excluded from further patupilone treatment due to 
peri-operative complications (2 patients) or toxicity (1 pa-
tient). Median OS from the time of the initial diagnosis 
was 21.5 months (95% CI, 17–25 months) and 1-year sur-
vival was 100% (95% CI, 80–100).
 Safety and Toxicity 
 Treatment with patupilone was generally well toler-
ated at a dose of 10 mg/m 2 , with no patients developing 
hematological toxicity ( table 2 ). Cumulative but revers-
ible sensory neuropathy grade 3 occurred in 2 of 9 pa-
tients (22%) after 8 months of treatment. The 2nd pa-
tient developed grade 4 diarrhea following his second 
patupilone application 3 weeks after second surgery. 
With a longer interval after second surgery and proac-
tive loperamide prescription, only mild diarrhea oc-
curred (grade  ^  2) in subsequently treated patients.
Two patients experienced peri-operative complications 
(meningitis) not considered to be adverse events of the 
study drug.
Table 1.  Patient and tumor characteristics (n = 9)
Patient
No.
Age
years
WHO
PS
Steroids
mg
Prior
treatment
Time, months
Dg–2nd surgery
III-tubulin Ki-67, %
(1st surgery)
MGMT Extent of
surgery
1 48 1 4 ST 10 +++ 15.1 NA ++
2 64 1 8 ST 25 +++ 10.4 NA +
3 55 1 12 ST, TMZ 7/7 9 +++ 26.5 NA +
4 42 1 4 ST, TMZ 7/7 18 ++ 27.7 UM 0
5 62 0 2 ST 4 +++ 24.1 UM ++
6 47 0 2 ST 6 + 9.5 UM +
7 54 0 0 ST 4 +++ 23.6 UM (+)
8 51 0 0 ST 6 ++ 10.7 UM 0
9 68 0 0 ST 8 +++ 15.6 UM 0
S teroids = Steroid treatment at study entry; PS = performance status; Dg = diagnosis; UM = unmethylated; NA = not assessed; 
ST = standard treatment [surgery, postoperative radiation and concomitant TMZ followed by adjuvant TMZ (1–6 cycles)]; TMZ 7/7 = 
TMZ 1-week-on, 1-week-off regimen for recurrent disease; III-tubulin: + = <10%; ++ = 10–50%; +++ = >50%; extent of surgery: 0 = 
no residual tumor on MRI; + = minimal residual tumor on MRI; ++ = subtotal tumor resection.
Table 2.  Outcome (n = 9)
Patient
No.
PFS
months
OS, months
after 2nd 
surgery
OS, months
after 1st
surgery
Cause
of death
Reasons for
discontinuation
Tox. TUNEL
%
Ki-67, %
at 2nd
surgery
F
rTBV
F 
Ki-67
Treatment
after
patupilone
1 1.5 11 22 PD PD 6.2 18.2 1.3 1.21 B, C
2 2.5 2.5 27.5 Co Tox. (1) D 1.9 12.1 1.7 1.16 none
3 1.5* 9 18 PD Tox. (2) 3.9 31.6 1.0 1.19 B, RT, C
4 1.5 21 39 PD PD 5.3 19.8 0.1 0.72 B, S, C
5 1.25 8.5 12.5 PD PD <1 32.9 2.1 1.37 B
6 2* 13.5 19.5 PD Tox (2) <1 42.8 0.1 4.5 B
7 9.75 17 21 PD PD PN <1 35.8 1.2 1.52 B
8 22 22 28 alive PD PN 4.5 28.8 0.14 2.69 none
9 1.25 6 14 PD PD <1 12.3 NA 0.79 B
 F Ki-67 = Ki-67 (after)/Ki-67 (before); F rTBV = rTBV (after)/rTBV (before); B = bevacizumab; C = CCNU; S = surgery; PD = 
progressive disease; D = diarrhea grade 4; PN = peripheral polyneuropathy grade 3; Co = perioperative complications; NA = not as-
sessed; Tox. = toxicity. * In patient 3 and 6 patupilone could only be administered prior to surgery due to post-surgical complications.
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 Neurocognitive Evaluation 
 Complete neuropsychological assessment before and 3 
months after surgery was performed in 6 of 9 patients 
(66%). Comparable levels of performance were achieved 
in the two assessments. Difficulties in word finding, 
memory impairment or visual-constructive problems 
corresponded with the tumor site. Deficiencies in execu-
tive functioning were observed irrespective of the tumor 
site and hemisphere. All patients showed reduced perfor-
mance in tests of selective attention and conceptual flex-
ibility before and 3 months after surgery.
 Biomarkers 
 Dynamic Contrast-Enhanced MRI 
 rTBV was measured prior and  1 5 days after the first 
patupilone application using MRI in 8 of 9 patients. The 
median fractional change was 1.0 (95% CI 0.62–0.92) and 
the mean rTBV change was 0.94. However, the rTBV 
change ranged from strong (max. 2.05) to substantial de-
creases (max. 0.04). Interestingly, rTBV was clearly re-
duced after treatment with patupilone in patient 8, which 
is seen by an 86% reduction in rTBV ( fig. 2 ).
 IHC of Apoptosis and   III-Tubulin, Class I
  -Tubulin Sequencing and Ki-67 at Second Surgery 
 Immunohistochemical assessment of apoptosis as an 
indicator of cell death induction  6 5 days following patu-
pilone administration demonstrated rather low apoptotic 
activity ranging from  ! 1% (4 cases) to a maximum of 
6.2%.   III-Tubulin, which is often overexpressed and 
thereby co-determines treatment resistance, was detect-
able in all 9 patients. There was strong   III-tubulin ex-
pression ( 1 50%) in 6 of 9 patients, intermediate expres-
sion (10–50%) in 2 patients and weak expression ( ! 10%) 
in only 1 patient ( fig. 3 ). In order to determine possible 
epothilone resistance mechanisms related to mutated 
class I   -tubulin, defining patupilone binding, the entire 
coding region of class I   -tubulin was sequenced in the 
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 Fig. 2. MR images after contrast enhance-
ment depict the extent of the tumor at 
baseline before treatment start with patu-
pilone ( a ) and 7 days later ( b ). The lower 
panels display the time courses of the con-
trast agent first pass in the GBM at baseline 
( c ) and 7 days later ( d ). The area under the 
contrast agent curve is proportional to 
TBV and shows its strong reduction after 
treatment. AU = Arbitrary units. 
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tumor biopsies of each patient. No deviations from the 
wild-type amino acid sequence could be identified, indi-
cating that other resistance mechanisms at the molecu-
lar-cellular level contributed to the differential treatment 
responses. The tumor proliferation marker Ki-67 was be-
tween 9 and 28% (mean 18%) at first surgery and between 
12 and 43% (mean 26%) at second surgery (p = 0.045), 
indicating a more aggressive behavior at the time of tu-
mor progression. In all but 2 patients, the difference fac-
tor   F Ki-67 was positive ( table 2 ).
 In summary, there was no significant correlation be-
tween OS or PFS6 and the rate of apoptosis,   III-tubulin 
expression, Ki-67 rate or change in rTBV.
 Discussion 
 In the treatment of recurrent or progressive GBM, 
there is no standard of care, and therefore a major need 
for novel therapeutic options exists. In this phase I/II sin-
gle-institution trial, we found that patupilone monother-
apy was well tolerated with a low toxicity profile and sta-
ble neurocognition, which allows for peri-operative and 
long-term application. Patupilone achieved high drug 
concentrations within the tumor tissue, with a high plas-
ma/tumor tissue ratio ( 1 30), most probably due to an im-
paired and pathological blood-tumor barrier and dimin-
ished drug clearance  [28, 29] . Although PFS6 was only 
22%, there were 2 long-lasting responses of 9.75 and 22 
months, and OS was noteworthy (median 11 months, 
TUNELKi-67 III-Tubulin
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8
 Fig. 3. Panel depicting Ki-67, TUNEL and   III-tubulin staining of three GBM from patients 5, 7 and 8. Bar = 100   m. 
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